Advertisement

Short-term hemodynamic effect of a new oral PGI2 analogue, Beraprost, in primary and secondary pulmonary hypertension

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      We conclude that Beraprost appears to be an effective and possibly available substitute for intravenous vasodilators in the treatment of primary PH and secondary PH. This preliminary report may offer favorable hemodynamic effects of a new oral PGI2 analogue in patients with PH.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Christman BW
        • McPherson CD
        • Newman JH
        • King GA
        • Bernard GR
        • Groves BM
        • Loyd JE
        An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.
        N Engl J Med. 1992; 327: 70-75
        • Watkins WD
        • Crone RK
        • Shannon DC
        • Levine L
        Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary hypertension.
        Lancet. 1980; 1: 1083
        • Nishio S
        • Matsuura H
        • Kawai N
        • Fukatsu Y
        • Hirano T
        • Nishikawa N
        • Kaneoka K
        • Umetsu T
        The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species.
        Jpn J Pharmacol. 1988; 47: 1-10
        • Higgenbottam T
        The place of prostacyclin in the clinical management of primary pulmonary hypertension.
        Am Rev Respir Dis. 1987; 136: 782-786
        • Rubin LJ
        • Mendoza J
        • Hood M
        • McGoon M
        • Barst R
        • William BW
        • Diehl JH
        • Crw J
        • Long W
        Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (Epoprosterol).
        Ann Intern Med. 1990; 112: 485-491
        • Cremona G
        • Higenbottam T
        Role of prostacyclin in the treatment of primary pulmonary hypertension.
        Am J Cardiol. 1995; 75: 67A-71A
        • Barst RJ
        • Rubin JL
        • McGoon MD
        • Caldwell EJ
        • Long WA
        • Levy PS
        Long-term continuous prostacyclin treatment improves survival in primary pulmonary hypertension.
        J Am Coll Cardiol. 1993; 21: 368A
        • Rich S
        Medical treatment of primary pulmonary hypertension: a bridge to transplantation?.
        Am J Cardiol. 1995; 75: 63A-66A
        • Jones DK
        • Higenbottom TW
        • Wallwork J
        Treatment of primary pulmonary hypertension with intravenous epoprosterol (Prostacyclin).
        Br Heart J. 1987; 57: 270-278
        • Murata T
        • Murai T
        • Kanai T
        • Ogaki Y
        • Sanai K
        • Kanda H
        • Sato S
        • Kajikawa N
        • Umetsu T
        • Matsuura H
        • Fukatsu Y
        • Isogaya M
        • Yamada N
        • Nishio S
        General pharmacology of Beraprost sodium, second communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects.
        Arzneim-Forsch Drug Res. 1989; 39: 867-876
        • Akiba T
        • Miyazaki M
        • Toda N
        Vasodilator actions of TRK-100, a new prostaglandin T2 analogue.
        Br J Pharmacology. 1986; 89: 703-711
        • Nishio S
        • Yamada N
        • Endoh T
        • Isogaya M
        • Fukatsu Y
        • Nishimura S
        • Kanai N
        • Umetsu T
        Effect of Beraprost sodium on peripheral circulatory disturbances induced by various stimuli.
        Drug Res. 1989; 39: 1229-1234
        • Kriner G
        • Siostrzonek P
        • Heinz G
        • Pabinger I
        • Roden M
        • Gossinger H
        Drug-testing in patients with pulmonary hypertension of unknown cause.
        Eur Heart J. 1992; 13: 776-780